CALGB-89803

Regimen

Experimental
Weekly bolus irinotecan + fluorouracil/leucovorin (IFL)
Control
Weekly bolus fluorouracil/leucovorin alone

Population

Stage III colon cancer after curative resection (N=1,264), adjuvant irinotecan-containing chemotherapy.

Key finding

NEGATIVE: No DFS or OS improvement with irinotecan + FL vs FL alone in stage III colon; toxicity including lethal toxicity significantly higher with irinotecan arm. Irinotecan adjuvant strategy abandoned.

Source: PMID 17687149

Timeline

    Guideline citations

    • NCCN Colon (p.103)